(CercleFinance.com) – ViiV Healthcare, a subsidiary of GSK, has announced its commitment to license its patents relating to long-acting cabotegravir (LA) for HIV pre-exposure prophylaxis (PrEP).
The group is beginning negotiations on voluntary license terms with the UN-backed Medicines Patent Pool (MPP).
ViiV Healthcare and MPP are working to agree terms and execute a voluntary license as soon as possible to enable large-scale access to cabotegravir LA for PrEP in low- and middle-income countries.
‘Voluntary licensing has enabled access to generic products containing another innovative medicine from ViiV Healthcare, dolutegravir, for at least 20 million people living with HIV in low- and middle-income countries, as of December 2021’ indicates the group.
‘We are pleased to make a significant contribution to this goal today by ensuring that viiV Healthcare patents do not impede access for people in low- and middle-income countries who could benefit from cabotegravir LA for the PrEP’ said Deborah Waterhouse, CEO of ViiV Healthcare.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
